Galectin Therapeutics Stock (NASDAQ: GALT)

Galectin Therapeutics Stock (NASDAQ:GALT), Trade Ideas

Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Stocks Photo by Jirapong Manustrong on Shutterstock

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

Mobile Infrastructure Corporation Common Stock

BEEP

GALT

Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying

Pre-Market Outlook

AUGG

ETST

SLGD

The Dow Jones closed higher by more than 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying

CNTX

SPRB

The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics Inc

The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Barnwell Industries</h3>
<ul>
<li>The Trade: Barnwell Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRN#NYSE">BRN</a>) 10% owner Sherwood Revocable Trust <a href="https://www.benzinga.com/quote/BRN/analyst-ratings">acquired a total of 52,150 shares</a> an average price of $2.80. To acquire these shares, it cost around $146,263.</li>
<li>What's Happening: On Feb. 20, Barnwell Industries announced a planned CEO succession.</li>
<li>What Barnwell Industries Does: Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas.</li>
</ul>
<h3 class="wp-block-heading">Mobile Infrastructure</h3>
<ul>
<li>The Trade: Mobile Infrastructure Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#NYSE">BEEP</a>) CEO Manuel Chavez III <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 55,116 shares at</a> at an average price of $ $3.39. To acquire these shares, it cost around $186,843.</li>
<li>What's Happening: Mobile Infrastructure is expected to issue its first quarter 2024 earnings release on May 15, 2024.</li>
<li>What Mobile Infrastructure Does: Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States.</li>
</ul>
<h3 class="wp-block-heading">Galectin Therapeutics</h3>
<ul>
<li>The Trade: Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) Director Kevin D Freeman <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,500 shares</a> at an average price of $2.98. The insider spent around $7,450 to buy those shares.</li>
<li>What's Happening: On April 9, HC Wainwright &amp; Co. analyst Ed Arce reiterated Galectin Therapeutics with a Buy and maintained a price target of $11.</li>
<li>What Galectin Therapeutics Does: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases.</li>
</ul>
Also Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38370420/general-motors-tesla-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Tesla And 3 Stocks To Watch Heading Into Tuesday</a>

HC Wainwright &amp; Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) with a Buy and maintains $11 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

<ul>
<li>Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosis &nbsp;</li>
<li>Fifth positive recommendation further supports favorable tolerability and safety profile of belapectin</li>
<li>Interim Phase 2b efficacy readout anticipated in Q4 2024</li>
</ul>

Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) shares increased by 20.66% to $3.62. The company's market cap stands at $224.0 million. </li>
<li>Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) stock moved upwards by 17.88% to $1.78. The company's market cap stands at $456.7 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares moved upwards by 17.67% to $2.73. The market value of their outstanding shares is at $4.6 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 15.5% to $2.98. The market value of their outstanding shares is at $33.1 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares moved upwards by 15.2% to $0.46. The company's market cap stands at $12.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock decreased by 17.1% to $1.39 during Friday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares fell 16.83% to $0.43. The market value of their outstanding shares is at $20.2 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock declined by 15.39% to $0.33. The market value of their outstanding shares is at $14.0 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares fell 15.25% to $0.12. The market value of their outstanding shares is at $4.7 million. </li>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares declined by 14.33% to $8.67. The company's market cap stands at $10.4 million. </li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock fell 13.86% to $2.55. The company's market cap stands at $9.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACOR

BIAF

CADL

EFTR

GCTK

Kintara Therapeutics, Inc. - Common Stock

KTRA

MEDS

OCGN

OTRK

PCSA

12 Health Care Stocks Moving In Friday's Intraday Session

Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) reported its Q3 earnings results on Monday, November 13, 2023 at 08:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Galectin Therapeutics missed estimated earnings by 50.0%, reporting an EPS of $-0.24 versus an estimate of $-0.16.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.06 which was followed by a 7.38% increase in the share price the next day.

To track all earnings releases for Galectin Therapeutics <a href="https://www.benzinga.com/quote/GALT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Galectin Therapeutics: Q3 Earnings Insights

Biotech

Guidance

Health Care

General

Galectin Therapeutics' $20.4M Of Cash And Cash Equivalents And $30M Remaining Available Under A $60M Line Of Credit Provided By Its Chairman Is Sufficient Cash To Fund Currently Planned Operations And R&D Activities Through At Least December 31, 2024

Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 71.43 percent decrease over losses of $(0.14) per share from the same period last year.

Galectin Therapeutics Q3 EPS $(0.24) Misses $(0.16) Estimate;

<a href="https://www.globenewswire.com/Tracker?data=kov7eXxBD8ZaYJyU4TQ8ug_P_LV_lshbqjNbDx9Y1mX_5t56pn_BD3VRV5MjyjZ79MKcSGIiuSk_CR3ZwzVVs5oZfkXq-bdPRc9yk7zpalhAfsEsF3bgI6hhzipVnCuLU04nUdxHcS_HmIW9RJfECd4kco4RinFmrVeCqbcxsHSchF694kCJ2LMQukiG1MYvPeGjA-vK8m0ZLqAVwXx-Pgec1aE1u-7L2YTWLKunr8RkOpoY6hV7fAQSG6JNTs2xcyr8Lj6sYT7JcnC_KH0IdWbHi2e_7wTrcVqP8AqBA3Q=" target="_blank">Galectin Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis. NAVIGATE is the first study of its kind and is a global effort that randomized 357 patients in 14 countries on five continents. The main efficacy objective is the primary prevention of esophageal varices. Interim topline data from the Phase 2b portion of NAVIGATE is expected in the&nbsp;fourth quarter&nbsp;of 2024. 
&nbsp;

Galectin Therapeutics Reports The Outcome Of The Fourth Data And Safety Monitoring Board Meeting For NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin In Patients With Portal Hypertension Caused By Non-Alcoholic SteatoHepatitis Live

<a href="https://www.globenewswire.com/Tracker?data=RPv6qhZT0JDURR_tLWAo_si-RPtTJ3hdowaI7kPKWUutV-1Lla00DHMUu8ojfTDmb-ln8dzn1D5xpZ2hrQzL-h6i5NmjbbBZ57I0xx3uijVKLUqEDTfzUm079QZBk_v8_BHFQPlZsyMJ3m0PPxcfA90lDodexun0MXG2K-R_sbIpc13URneKEMDfsQhsiLLGLM6T0vKYUmR-OxPw9-vr7m2a64hBQUfaGRmYBJJwJKYuNzU3m8zIgNlc_T_6Z7RUYtje3Rdm14E5XtV8C3uiCm_f67OFkQJrBvybgvhKujA=">Galectin Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry's preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session. The presentation, titled "Targeting Activated Macrophages to Improve Liver Cirrhosis: The Discovery and Clinical Translation of Belapectin," will take place Wednesday, September 27,&nbsp;at&nbsp;2:25 PM&nbsp;EDT and will be delivered by Dr. Pol F. Boudes, M.D., Chief Medical Officer of Galectin Therapeutics. &nbsp;
Boudes commented: "The role of activated macrophages in the establishment and progression of liver cirrhosis is predominant1. These cells, when activated, invade the liver, and produce galectin-3, a pro-inflammatory and pro-fibrotic molecule. Belapectin is a galectin-3 inhibitor that, thanks to its unique molecular structure, is captured by activated macrophages and can inhibit galectin-3 at its site of production. Liver cirrhosis has been a field that has been neglected for far too long by drug developers and the Discovery on Target meeting is an excellent opportunity to familiarize a large audience to the consequences of liver cirrhosis and portal hypertension and highlight the opportunity our belapectin program offers for patients affected by this severe disease."
1 Ramachandran, et al. Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis. Nature Reviews Gastroenterology and Hepatology 2020;17:457-472.
About Belapectin Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH/MASH and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Belapectin binds to galectin-3 and disrupts its function. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. A Phase 2 study showed belapectin may prevent the development of esophageal varices in NASH cirrhosis, and these results provide the basis for the conduct of the NAVIGATE trial. The NAVIGATE trial (<a href="https://www.globenewswire.com/Tracker?data=zr_V0GAXlATbWcrGeSEkYqvYgo6Ka-mLoimt4RHOz7Y0QkvWo-UEmqjc7I0_2Z3jNi-dWowObKF2oZtc6OwGhRVkGNwb0bXDhxRSajFdmZuKacxGXvgF1xTpSIA0cZamWKf7J1EMo0B3s_32RV-U-mChvkUIxLkjzLzhIXqKgBoCborpVNNvep2W-mq6L5iH_DS4WsbdrrpThHaYVaEtj1Brb8DgLElZZfhYUMIt2QRcA7WBGbOZzh3hiUy1_0ylxTvf2kH2ZeJM7GIjigqnYw==">www.NAVIGATEnash.com</a>), titled, "A Seamless Adaptive Phase 2b/3, Double-Blind, Randomized, Placebo-controlled Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis," is fully enrolled, and further details are posted on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=w2EJz6wKHz9DwrjtXJPMY0Pqkqp3YXHKmKKzrtozwr8dSAfuuu1tnAMNRcaJCs18JEgWY0L_PVXMQCEei3G7yL-XPRmTzPVwrAkl4tdNkEq5kQ9-LMm9QpdIEWsc7hpudOB73iiDmPL6hQIbkPK-XZbDpd-XXWE96-pGuuAdxcMpPRs8EaxMVgnVyZSZpYFx7RMDxFZSIY2ZrFjx_YQVdM-fTTVNPNohfo-ojLnIBweUUIlTiCiiEj3lb4f9lH4ZH1IsBbRrQNwdDfsO0mZmwA==">www.clinicaltrials.gov</a>&nbsp;(NCT04365868). Galectin-3 has a significant role in cancer, and the Company has supported a Phase 1b study in combined immunotherapy of belapectin and Keytruda in advanced melanoma and in head and neck cancer. This trial provided a strong rationale for moving forward into a Company-sponsored Phase 2 development program, which the company is exploring.
About liver cirrhosis due to NASH/MASH and portal hypertension Non-alcoholic steatohepatitis (NASH), also known as MASH, has become a common disease of the liver with the rise in obesity and other metabolic diseases. NASH is estimated to affect up to 28 million people in the U.S. It is characterized by the presence of excess fat in the liver along with inflammation and hepatocyte damage (ballooning) in people who consume little or no alcohol. Over time, patients with NASH can develop excessive fibrosis, or scarring of the liver, and ultimately liver cirrhosis. Liver cirrhosis is further complicated by portal hypertension which is one of the main mechanism leading to decompensated liver cirrhosis. It is estimated that as many as 1 to 2 million individuals in the U.S. will develop cirrhosis as a result of NASH/MASH, for which liver transplantation is the only curative treatment available. Approximately 9,000 liver transplants are performed annually in the U.S. There are no drug therapies approved for the treatment of liver cirrhosis.

Galectin Therapeutics To Present Update On Its Belapectin Liver Cirrhosis Program At The 20th Edition Of Discovery On Target Meeting, In Boston, September 25-28, 2023

Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.21) by 28.57 percent. This is a 6.25 percent increase over losses of $(0.16) per share from the same period last year.

Galectin Therapeutics Q2 EPS $(0.15) Beats $(0.21) Estimate

The Dow Jones closed higher by more than 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Scott&#39;s Liquid Gold </h3>
<ul>
<li>The Trade: Scott&#39;s Liquid Gold-Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/slgd#OTC">SLGD</a>) Director Daniel Roller <a href="https://www.benzinga.com/quote/SLGD/analyst-ratings"> acquired a total of 794,067 shares </a> an average price of $0.33. To acquire these shares, it cost around $262,042.</li>
<li>What&rsquo;s Happening: The company&rsquo;s shares jumped around 82% over the past six months.</li>
<li>What Scott&#39;s Liquid Gold Does: Scott&#39;s Liquid Gold Inc develop, market, and sell high-quality, high-value household and personal care products.</li>
</ul>
<h3>Augusta Gold </h3>
<ul>
<li>The Trade: Augusta Gold Corp. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/augg#OTC">AUGG</a>) Executive Chairman Richard Warke <a href="https://www.benzinga.com/quote/RCG/analyst-ratings"> acquired a total of 5,000 shares </a> at an average price of $0.80. The insider spent around $4,000.</li>
<li>What&rsquo;s Happening: Augusta Gold recently said that it is advancing on its plan to complete a Feasibility Study at its 100% owned Reward Project.</li>
<li>What Augusta Gold Does: Augusta Gold Corp is an exploration-stage company. The company is primarily engaged in the acquisition and exploration of gold properties. It operates Bullfrog Project, located in Beatty town of Las Vegas, Nevada.</li>
</ul>
<h3>Galectin Therapeutics</h3>
<ul>
<li>The Trade: Galectin Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/galt#NASDAQ">GALT</a>) Director Kary Eldred <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 1,598 shares </a> at an average price of $1.79. To acquire these shares, it cost around $2,854.</li>
<li>What&rsquo;s Happening: Galectin Therapeutics posted a narrower-than-expected quarterly loss.</li>
<li>What Galectin Therapeutics Does: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/07/33316698/investor-sentiment-declines-after-nasdaq-falls-2"> Investor Sentiment Declines After Nasdaq Falls 2% </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h3>Earth Science Tech </h3>
<ul>
<li>The Trade: Earth Science Tech, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/etst#OTC">ETST</a>) CEO Giorgio R Saumat <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 50,002 shares </a> at an average price of $0.08. The insider spent $ $4,050 to buy those shares.</li>
<li>What&rsquo;s Happening: Earth Science Tech named Gabrielle Schuster as Chief Financial Officer of the Company.</li>
<li>What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.</li>
</ul>

Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 11.76 percent decrease over losses of $(0.17) per share from the same period last year.

Galectin Therapeutics Q1 EPS $(0.19) Beats $(0.21) Estimate; The Company Had $17.8 Million Of Cash And Cash Equivalents, And Expects That It Will Require More Cash To Fund Operations After December 31, 2024

Galectin Therapeutics Reports FY22 EPS Loss Of (0.65), Down From $(0.52) Loss A Year Ago

The objective of this third independent DSMB was to further review the emerging tolerance and safety profiles of belapectin. Based on its deliberation, which included an unblinded review of the data collected thus far, the DSMB concluded that NAVIGATE can continue as designed, without modifications.

Galectin Therapeutics Reported The Outcome Of Its Third Data And Safety Monitoring Board Meeting For NAVIGATE Phase 2B/3 Study Of Belapectin For Liver Cirrhosis Caused By NASH, Interim Data From The Phase 2B Portion Is Expected In Q4 Of 2024

&nbsp;<a href="https://www.globenewswire.com/Tracker?data=JIMre3RVafuLsjO0uFzVoC8A3x66SV3bBI7NgRfoBEihAIcZUeuhNnsZVxU4YmdAzPMKaXvIbJNiXRro_OQ9Qe49HUJVPYfOeVzcfv_kgc_BCuEooxEOngM9e_PYNfgWjL6RfFCTM8hG0eY8OX24Tu8ULKjVCknFeTyL3ymz7OQlFmwg-I3XAPIb-ri-kPhgkwtIb6RDe-qdHiwDxQOobQM_2YlwLHL-YUK-GyXkwRBKC0b6Ov3SZG11Awhsznh9YKAbjK3yZuZORj5ngYMpwrUdgc4Gai1QyQ7Gf2gVXqLzpSPanc2BhdcII790JU1RFrZEaKKBjRv9u-jH-kp9fCVC1Kkx3ZjocRDTQfkny6CrqR8zHCdDQWd3_Yv_d-c-IUxfKShtYOgHPt4LyIsY-7ustx5w5U-h_kbNPufvxCt6arYgU2TCCzuffoxuU_IqLgGWJJqN3qdUCier-4g-z6y8TR_tp7EHgHZhVU3jRjPwOLPA7MethVNZi0d4NQ9SbXPldD4UYoMmTRIvKjpGQg==" target="_blank">Galectin Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). The last patient was randomized into NAVIGATE at the end of February 2023. In order to be randomized, the screening process documented the presence of clinical signs of portal hypertension and validated the absence of esophageal and/or gastric varices by a central adjudication of video recording of upper esophago-gastric endoscopies. NAVIGATE has randomized 357 patients, above its initial objective of approximately 315 patients. 
&nbsp;
NAVIGATE is the first study of its kind and is a global effort that recruited patients in 14 countries and on five continents. The main efficacy objective is the primary prevention of esophageal varices. Patients enrolled in the study have cirrhosis caused by NASH and, because of the advancing cirrhotic process, have already developed portal hypertension but have not yet developed dilated veins in the esophagus known as esophageal varices, a clinically concerning complication of portal hypertension. Portal hypertension is the consequence of the unrelented inflammatory and fibrotic process occurring in the liver and dramatically increases the risk of developing esophageal varices, a potentially life-threatening complication of liver cirrhosis.
Dr. Pol Boudes, M.D., Chief Medical Officer of Galectin Therapeutics, said: &quot;We are very pleased to achieve our randomization objective for this study, the first of its kind to address liver cirrhosis with portal hypertension. The treatment period of the phase 2b portion is 18 months; therefore, the topline results of the interim analysis are expected in the&nbsp;fourth quarter&nbsp;of 2024. This will be a very important milestone for patients affected by this disease and for their families, and we hope to demonstrate a positive risk benefit for belapectin.&quot;
Mr. Joel Lewis, the Company&#39;s President and Chief Executive Officer said: &quot;We are gratified to reach this important milestone. The last randomization will allow us to focus on efficiently executing our program and other stated goals for the rest of the year. On behalf of the whole team at Galectin Therapeutics, I again want to personally thank our investigators and their teams, along with all of the patients in the trial, for participating in this innovative study. I also am extremely grateful for the commitment and dedication of all of our employees in enabling us to reach this milestone.&quot;

Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis

The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h2>Spruce Biosciences </h2>
<ul>
<li>The Trade: Spruce Biosciences Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprb#NASDAQ">SPRB</a>) 10% owner Novo Holdings AS <a href="https://www.benzinga.com/sec/insider-trades/"> bought a total of 2,208,000 shares </a> at an average price of $3.17. To acquire these shares, it cost around $7 million.</li>
<li>What&rsquo;s Happening: Spruce Biosciences announced a $53.6 million private placement financing.</li>
<li>What Spruce Biosciences Does: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders.</li>
</ul>
<h2>Dakota Gold </h2>
<ul>
<li>The Trade: Dakota Gold Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dc#NYSE">DC</a>) Director Alice D Schroeder <a href="https://www.benzinga.com/quote/OESX/analyst-ratings"> acquired a total 20,044 shares </a> at an average price of $2.96. The insider spent around $59.33 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: The company&rsquo;s stock tumbled 25% over the past six months.</li>
<li>What Dakota Gold Does: Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/23/02/30985245/top-5-tech-and-telecom-stocks-that-you-may-want-to-dump-in-q1-2023"> Top 5 Tech And Telecom Stocks That You May Want To Dump In Q1 2023 </a>
<h2>Context Therapeutics</h2>
<ul>
<li>The Trade: Context Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cntx#NASDAQ">CNTX</a>) CEO Martin Lehr <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,823 shares </a> at an average price of $0.84. To acquire these shares, it cost around $4.9 thousand.</li>
<li>What&rsquo;s Happening: Context Therapeutics recently said two patients have achieved a confirmed partial response among the first 12 patients enrolled in Phase 2 OATH trial of ONA-XR in endometrial cancer.</li>
<li>What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.</li>
</ul>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h2>Galectin Therapeutics </h2>
<ul>
<li>The Trade: Galectin Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/galt#NASDAQ">GALT</a>) Director Kary Eldred <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 1,000 shares </a> at an average price of $1.59. The insider spent $1.59 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: Galectin Therapeutics, during November, posted a Q3 loss of $0.14 per share.</li>
<li>What Galectin Therapeutics Does: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company.</li>
</ul>

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Galectin Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/galt-stock-quote/">GALT</a>) just reported results for the fourth quarter of 2023.<ul><li>Galectin Therapeutics reported earnings per share of -16 cents. This met the analyst estimate for EPS of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/galt-stock-earnings-galectin-therapeutics-for-q4-of-2023/">GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023

Galectin Therapeutics, Titan Pharmaceuticals, Outset Medical among healthcare movers

Madrigal announces US launch of NASH/MASH drug Rezdiffra

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inogen (INGN – Research Report) and Galectin Therapeutics (GALT –...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inogen (INGN) and Galectin Therapeutics (GALT)

Catalyst Watch: Boeing hearing, Bitcoin halving event and new eyes on Reddit

Wall Street Breakfast: The Week Ahead

Hepion ends Phase 2 study for NASH drug due to cash restraints

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

ADIL

AKRO

ALAB

ALLY

ALUR

ARWR

ASCLF

AUNA

BIDU

BLZE

BNTC

CLSK

COIN

CPRI

CTRI

ETNB

FUJIY

GDTC

GILD

GLMD

GOOG

HEPA

IBTA

IDCC

INGN

INTJ

IONS

ISRG

ISVLF

KAMN

LGVN

LIFW

MARA

MDGL

MSTR

NFLX

NKGN

NKLA

PERI

PINS

RDDT

RIOT

RIVN

SBGI

SCHW

SGMT

SIRI

SONY

TERN

TTNP

VKTX

VLKAF

WBUY

ZCMD

Press Releases

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis

Management

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis